Our results suggest that combining inhibition of BCL-2 with drugs that reduce the expression or activity of MCL-1 may prove valuable for targeting auto-reactive or malignant PC in autoimmune disease or multiple myeloma, respectively. The gene discussed is MCL1; the disease is pachyonychia congenita.